1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Toxins and Superantigens of Group A Streptococci

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: Blake A. Shannon1, John K. McCormick2, Patrick M. Schlievert3
  • Editors: Vincent A. Fischetti4, Richard P. Novick5, Joseph J. Ferretti6, Daniel A. Portnoy7, Miriam Braunstein8, Julian I. Rood9
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Department of Microbiology and Immunology, Western University and The Lawson Health Research Institute, London, Ontario, Canada N6A 4V2; 2: Department of Microbiology and Immunology, Western University and The Lawson Health Research Institute, London, Ontario, Canada N6A 4V2; 3: Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242; 4: The Rockefeller University, New York, NY; 5: Skirball Institute for Molecular Medicine, NYU Medical Center, New York, NY; 6: Department of Microbiology & Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK; 7: Department of Molecular and Cellular Microbiology, University of California, Berkeley, Berkeley, CA; 8: Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, NC; 9: Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia
  • Source: microbiolspec February 2019 vol. 7 no. 1 doi:10.1128/microbiolspec.GPP3-0054-2018
  • Received 03 December 2018 Accepted 10 December 2018 Published 08 February 2019
  • Patrick M. Schlievert, [email protected]
image of Toxins and Superantigens of Group A Streptococci
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Toxins and Superantigens of Group A Streptococci, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/7/1/GPP3-0054-2018-1.gif /docserver/preview/fulltext/microbiolspec/7/1/GPP3-0054-2018-2.gif
  • Abstract:

    (i.e., the group A ) is a human-restricted and versatile bacterial pathogen that produces an impressive arsenal of both surface-expressed and secreted virulence factors. Although surface-expressed virulence factors are clearly vital for colonization, establishing infection, and the development of disease, the secreted virulence factors are likely the major mediators of tissue damage and toxicity seen during active infection. The collective exotoxin arsenal of is rivaled by few bacterial pathogens and includes extracellular enzymes, membrane active proteins, and a variety of toxins that specifically target both the innate and adaptive arms of the immune system, including the superantigens; however, despite their role in disease, each of these virulence factors has likely evolved with humans in the context of asymptomatic colonization and transmission. In this article, we focus on the biology of the true secreted exotoxins of the group A , as well as their roles in the pathogenesis of human disease.

  • Citation: Shannon B, McCormick J, Schlievert P. 2019. Toxins and Superantigens of Group A Streptococci. Microbiol Spectrum 7(1):GPP3-0054-2018. doi:10.1128/microbiolspec.GPP3-0054-2018.

References

1. Nizet V, Beall B, Bast DJ, Datta V, Kilburn L, Low DE, De Azavedo JC. 2000. Genetic locus for streptolysin S production by group A streptococcus. Infect Immun 68:4245–4254 http://dx.doi.org/10.1128/IAI.68.7.4245-4254.2000. [PubMed]
2. Molloy EM, Cotter PD, Hill C, Mitchell DA, Ross RP. 2011. Streptolysin S-like virulence factors: the continuing sagA. Nat Rev Microbiol 9:670–681 http://dx.doi.org/10.1038/nrmicro2624. [PubMed]
3. Datta V, Myskowski SM, Kwinn LA, Chiem DN, Varki N, Kansal RG, Kotb M, Nizet V. 2005. Mutational analysis of the group A streptococcal operon encoding streptolysin S and its virulence role in invasive infection. Mol Microbiol 56:681–695 http://dx.doi.org/10.1111/j.1365-2958.2005.04583.x. [PubMed]
4. Goldmann O, Sastalla I, Wos-Oxley M, Rohde M, Medina E. 2009. Streptococcus pyogenes induces oncosis in macrophages through the activation of an inflammatory programmed cell death pathway. Cell Microbiol 11:138–155 http://dx.doi.org/10.1111/j.1462-5822.2008.01245.x. [PubMed]
5. Miyoshi-Akiyama T, Takamatsu D, Koyanagi M, Zhao J, Imanishi K, Uchiyama T. 2005. Cytocidal effect of Streptococcus pyogenes on mouse neutrophils in vivo and the critical role of streptolysin S. J Infect Dis 192:107–116 http://dx.doi.org/10.1086/430617. [PubMed]
6. Flaherty RA, Puricelli JM, Higashi DL, Park CJ, Lee SW. 2015. Streptolysin S promotes programmed cell death and enhances inflammatory signaling in epithelial keratinocytes during group A Streptococcus infection. Infect Immun 83:4118–4133 http://dx.doi.org/10.1128/IAI.00611-15. [PubMed]
7. Carr A, Sledjeski DD, Podbielski A, Boyle MDP, Kreikemeyer B. 2001. Similarities between complement-mediated and streptolysin S-mediated hemolysis. J Biol Chem 276:41790–41796 http://dx.doi.org/10.1074/jbc.M107401200. [PubMed]
8. Higashi DL, Biais N, Donahue DL, Mayfield JA, Tessier CR, Rodriguez K, Ashfeld BL, Luchetti J, Ploplis VA, Castellino FJ, Lee SW. 2016. Activation of band 3 mediates group A Streptococcus streptolysin S-based beta-haemolysis. Nat Microbiol 1:15004 http://dx.doi.org/10.1038/nmicrobiol.2015.4. [PubMed]
9. Sumitomo T, Nakata M, Higashino M, Jin Y, Terao Y, Fujinaga Y, Kawabata S. 2011. Streptolysin S contributes to group A streptococcal translocation across an epithelial barrier. J Biol Chem 286:2750–2761 http://dx.doi.org/10.1074/jbc.M110.171504. [PubMed]
10. Betschel SD, Borgia SM, Barg NL, Low DE, De Azavedo JCS. 1998. Reduced virulence of group A streptococcal Tn916 mutants that do not produce streptolysin S. Infect Immun 66:1671–1679. [PubMed]
11. Kehoe MA, Miller L, Walker JA, Boulnois GJ. 1987. Nucleotide sequence of the streptolysin O (SLO) gene: structural homologies between SLO and other membrane-damaging, thiol-activated toxins. Infect Immun 55:3228–3232. [PubMed]
12. Tweten RK, Hotze EM, Wade KR. 2015. The unique molecular choreography of giant pore formation by the cholesterol-dependent cytolysins of Gram-positive bacteria. Annu Rev Microbiol 69:323–340 http://dx.doi.org/10.1146/annurev-micro-091014-104233. [PubMed]
13. Bhakdi S, Tranum-Jensen J, Sziegoleit A. 1985. Mechanism of membrane damage by streptolysin-O. Infect Immun 47:52–60. [PubMed]
14. Shewell LK, Harvey RM, Higgins MA, Day CJ, Hartley-Tassell LE, Chen AY, Gillen CM, James DBA, Alonzo F III, Torres VJ, Walker MJ, Paton AW, Paton JC, Jennings MP. 2014. The cholesterol-dependent cytolysins pneumolysin and streptolysin O require binding to red blood cell glycans for hemolytic activity. Proc Natl Acad Sci U S A 111:E5312–E5320 http://dx.doi.org/10.1073/pnas.1412703111. [PubMed]
15. Timmer AM, Timmer JC, Pence MA, Hsu LC, Ghochani M, Frey TG, Karin M, Salvesen GS, Nizet V. 2009. Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J Biol Chem 284:862–871 http://dx.doi.org/10.1074/jbc.M804632200. [PubMed]
16. Uchiyama S, Döhrmann S, Timmer AM, Dixit N, Ghochani M, Bhandari T, Timmer JC, Sprague K, Bubeck-Wardenburg J, Simon SI, Nizet V. 2015. Streptolysin O rapidly impairs neutrophil oxidative burst and antibacterial responses to group A Streptococcus. Front Immunol 6:581 http://dx.doi.org/10.3389/fimmu.2015.00581.
17. Ruiz N, Wang B, Pentland A, Caparon M. 1998. Streptolysin O and adherence synergistically modulate proinflammatory responses of keratinocytes to group A streptococci. Mol Microbiol 27:337–346 http://dx.doi.org/10.1046/j.1365-2958.1998.00681.x. [PubMed]
18. Michos A, Gryllos I, Håkansson A, Srivastava A, Kokkotou E, Wessels MR. 2006. Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the group A streptococcal toxin, NAD-glycohydrolase. J Biol Chem 281:8216–8223 http://dx.doi.org/10.1074/jbc.M511674200. [PubMed]
19. Madden JC, Ruiz N, Caparon M. 2001. Cytolysin-mediated translocation (CMT): a functional equivalent of type III secretion in Gram-positive bacteria. Cell 104:143–152 http://dx.doi.org/10.1016/S0092-8674(01)00198-2.
20. Sharma O, O’Seaghdha M, Velarde JJ, Wessels MR. 2016. NAD+-glycohydrolase promotes intracellular survival of group A Streptococcus. PLoS Pathog 12:e1005468 http://dx.doi.org/10.1371/journal.ppat.1005468. [PubMed]
21. Bricker AL, Cywes C, Ashbaugh CD, Wessels MR. 2002. NAD+-glycohydrolase acts as an intracellular toxin to enhance the extracellular survival of group A streptococci. Mol Microbiol 44:257–269 http://dx.doi.org/10.1046/j.1365-2958.2002.02876.x. [PubMed]
22. Zhu L, Olsen RJ, Lee JD, Porter AR, DeLeo FR, Musser JM. 2017. Contribution of Secreted NADase and streptolysin O to the pathogenesis of epidemic serotype M1 Streptococcus pyogenes infections. Am J Pathol 187:605–613 http://dx.doi.org/10.1016/j.ajpath.2016.11.003. [PubMed]
23. Sierig G, Cywes C, Wessels MR, Ashbaugh CD. 2003. Cytotoxic effects of streptolysin O and streptolysin S enhance the virulence of poorly encapsulated group A streptococci. Infect Immun 71:446–455 http://dx.doi.org/10.1128/IAI.71.1.446-455.2003. [PubMed]
24. Fontaine MC, Lee JJ, Kehoe MA. 2003. Combined contributions of streptolysin O and streptolysin S to virulence of serotype M5 Streptococcus pyogenes strain Manfredo. Infect Immun 71:3857–3865 http://dx.doi.org/10.1128/IAI.71.7.3857-3865.2003. [PubMed]
25. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. 1989. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 56:27–35 http://dx.doi.org/10.1016/0092-8674(89)90980-X.
26. Dick GF, Dick GH. 1924. A skin test for susceptibility to scarlet fever. JAMA 82:256–266 http://dx.doi.org/10.1001/jama.1924.02650300011003.
27. Watson DW. 1960. Host-parasite factors in group A streptococcal infections. Pyrogenic and other effects of immunologic distinct exotoxins related to scarlet fever toxins. J Exp Med 111:255–284 http://dx.doi.org/10.1084/jem.111.2.255. [PubMed]
28. Schlievert PM, Bettin KM, Watson DW. 1979. Reinterpretation of the Dick test: role of group A streptococcal pyrogenic exotoxin. Infect Immun 26:467–472. [PubMed]
29. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. 1990. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 17:251–272 http://dx.doi.org/10.3109/10408419009105728. [PubMed]
30. Kotb M. 1995. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 8:411–426 http://dx.doi.org/10.1128/CMR.8.3.411. [PubMed]
31. Marrack P, Kappler J. 1990. The staphylococcal enterotoxins and their relatives. Science 248:1066 http://dx.doi.org/10.1126/science.248.4959.1066-b. [PubMed]
32. McCormick JK, Yarwood JM, Schlievert PM. 2001. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 55:77–104 http://dx.doi.org/10.1146/annurev.micro.55.1.77. [PubMed]
33. Assimacopoulos AP, Stoehr JA, Schlievert PM. 1997. Mitogenic factors from group G streptococci associated with scarlet fever and streptococcal toxic shock syndrome. Adv Exp Med Biol 418:109–114 http://dx.doi.org/10.1007/978-1-4899-1825-3_27. [PubMed]
34. Miyoshi-Akiyama T, Zhao J, Kato H, Kikuchi K, Totsuka K, Kataoka Y, Katsumi M, Uchiyama T. 2003. Streptococcus dysgalactiae-derived mitogen (SDM), a novel bacterial superantigen: characterization of its biological activity and predicted tertiary structure. Mol Microbiol 47:1589–1599 http://dx.doi.org/10.1046/j.1365-2958.2003.03411.x. [PubMed]
35. Proft T, Moffatt SL, Weller KD, Paterson A, Martin D, Fraser JD. 2000. The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation. J Exp Med 191:1765–1776 http://dx.doi.org/10.1084/jem.191.10.1765. [PubMed]
36. Paillot R, Darby AC, Robinson C, Wright NL, Steward KF, Anderson E, Webb K, Holden MTG, Efstratiou A, Broughton K, Jolley KA, Priestnall SL, Marotti Campi MC, Hughes MA, Radford A, Erles K, Waller AS. 2010. Identification of three novel superantigen-encoding genes in Streptococcus equi subsp. zooepidemicus, szeF, szeN, and szeP. Infect Immun 78:4817–4827 http://dx.doi.org/10.1128/IAI.00751-10.
37. Paillot R, Robinson C, Steward K, Wright N, Jourdan T, Butcher N, Heather Z, Waller AS. 2010. Contribution of each of four superantigens to Streptococcus equi-induced mitogenicity, gamma interferon synthesis, and immunity. Infect Immun 78:1728–1739 http://dx.doi.org/10.1128/IAI.01079-09.
38. Banks DJ, Porcella SF, Barbian KD, Beres SB, Philips LE, Voyich JM, DeLeo FR, Martin JM, Somerville GA, Musser JM. 2004. Progress toward characterization of the group A Streptococcus metagenome: complete genome sequence of a macrolide-resistant serotype M6 strain. J Infect Dis 190:727–738 http://dx.doi.org/10.1086/422697. [PubMed]
39. Beres SB, Sylva GL, Barbian KD, Lei B, Hoff JS, Mammarella ND, Liu MY, Smoot JC, Porcella SF, Parkins LD, Campbell DS, Smith TM, McCormick JK, Leung DY, Schlievert PM, Musser JM. 2002. Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci U S A 99:10078–10083 http://dx.doi.org/10.1073/pnas.152298499. [PubMed]
40. Ferretti JJ, McShan WM, Ajdic D, Savic DJ, Savic G, Lyon K, Primeaux C, Sezate S, Suvorov AN, Kenton S, Lai HS, Lin SP, Qian Y, Jia HG, Najar FZ, Ren Q, Zhu H, Song L, White J, Yuan X, Clifton SW, Roe BA, McLaughlin R. 2001. Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci U S A 98:4658–4663 http://dx.doi.org/10.1073/pnas.071559398. [PubMed]
41. Nakagawa I, Kurokawa K, Yamashita A, Nakata M, Tomiyasu Y, Okahashi N, Kawabata S, Yamazaki K, Shiba T, Yasunaga T, Hayashi H, Hattori M, Hamada S. 2003. Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale genomic rearrangement in invasive strains and new insights into phage evolution. Genome Res 13:1042–1055 http://dx.doi.org/10.1101/gr.1096703. [PubMed]
42. Smoot JC, Barbian KD, Van Gompel JJ, Smoot LM, Chaussee MS, Sylva GL, Sturdevant DE, Ricklefs SM, Porcella SF, Parkins LD, Beres SB, Campbell DS, Smith TM, Zhang Q, Kapur V, Daly JA, Veasy LG, Musser JM. 2002. Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc Natl Acad Sci U S A 99:4668–4673 http://dx.doi.org/10.1073/pnas.062526099. [PubMed]
43. Commons RJ, Smeesters PR, Proft T, Fraser JD, Robins-Browne R, Curtis N. 2014. Streptococcal superantigens: categorization and clinical associations. Trends Mol Med 20:48–62 http://dx.doi.org/10.1016/j.molmed.2013.10.004. [PubMed]
44. Li H, Llera A, Malchiodi EL, Mariuzza RA. 1999. The structural basis of T cell activation by superantigens. Annu Rev Immunol 17:435–466 http://dx.doi.org/10.1146/annurev.immunol.17.1.435. [PubMed]
45. Mitchell DT, Levitt DG, Schlievert PM, Ohlendorf DH. 2000. Structural evidence for the evolution of pyrogenic toxin superantigens. J Mol Evol 51:520–531 http://dx.doi.org/10.1007/s002390010116. [PubMed]
46. Sundberg EJ, Andersen PS, Schlievert PM, Karjalainen K, Mariuzza RA. 2003. Structural, energetic, and functional analysis of a protein-protein interface at distinct stages of affinity maturation. Structure 11:1151–1161 http://dx.doi.org/10.1016/S0969-2126(03)00187-4.
47. Bueno C, Criado G, McCormick JKJK, Madrenas J. 2007. T cell signalling induced by bacterial superantigens. Chem Immunol Allergy 93:161–180 http://dx.doi.org/10.1159/000100894. [PubMed]
48. Sundberg EJ, Li H, Llera AS, McCormick JK, Tormo J, Schlievert PM, Karjalainen K, Mariuzza RA. 2002. Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexes. Structure 10:687–699 http://dx.doi.org/10.1016/S0969-2126(02)00759-1.
49. Li H, Llera A, Tsuchiya D, Leder L, Ysern X, Schlievert PM, Karjalainen K, Mariuzza RA. 1998. Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity 9:807–816 http://dx.doi.org/10.1016/S1074-7613(00)80646-9.
50. Fields BA, Malchiodi EL, Li H, Ysern X, Stauffacher CV, Schlievert PM, Karjalainen K, Mariuzza RA. 1996. Crystal structure of a T-cell receptor β-chain complexed with a superantigen. Nature 384:188–192 http://dx.doi.org/10.1038/384188a0. [PubMed]
51. Nur-ur Rahman AK, Bonsor DA, Herfst CA, Pollard F, Peirce M, Wyatt AW, Kasper KJ, Madrenas J, Sundberg EJ, McCormick JK. 2011. The T cell receptor β-chain second complementarity determining region loop (CDR2β) governs T cell activation and Vβ specificity by bacterial superantigens. J Biol Chem 11:286.
52. Li PL, Tiedemann RE, Moffat SL, Fraser JD. 1997. The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action. J Exp Med 186:375–383 http://dx.doi.org/10.1084/jem.186.3.375. [PubMed]
53. McCormick JK, Tripp TJ, Olmsted SB, Matsuka YV, Gahr PJ, Ohlendorf DH, Schlievert PM. 2000. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J Immunol 165:2306–2312 http://dx.doi.org/10.4049/jimmunol.165.4.2306. [PubMed]
54. Swietnicki W, Barnie AM, Dyas BK, Ulrich RG. 2003. Zinc binding and dimerization of Streptococcus pyogenes pyrogenic exotoxin C are not essential for T-cell stimulation. J Biol Chem 278:9885–9895 http://dx.doi.org/10.1074/jbc.M206957200. [PubMed]
55. Tripp TJ, McCormick JK, Webb JM, Schlievert PM. 2003. The zinc-dependent major histocompatibility complex class II binding site of streptococcal pyrogenic exotoxin C is critical for maximal superantigen function and toxic activity. Infect Immun 71:1548–1550 http://dx.doi.org/10.1128/IAI.71.3.1548-1550.2003. [PubMed]
56. Kasper KJ, Xi W, Rahman AK, Nooh MM, Kotb M, Sundberg EJ, Madrenas J, McCormick JK. 2008. Molecular requirements for MHC class II α-chain engagement and allelic discrimination by the bacterial superantigen streptococcal pyrogenic exotoxin C. J Immunol 181:3384–3392 http://dx.doi.org/10.4049/jimmunol.181.5.3384. [PubMed]
57. Li Y, Li H, Dimasi N, McCormick JKJK, Martin R, Schuck P, Schlievert PMPM, Mariuzza RA. 2001. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity 14:93–104 http://dx.doi.org/10.1016/S1074-7613(01)00092-9. [PubMed]
58. Petersson K, Thunnissen M, Forsberg G, Walse B. 2002. Crystal structure of a SEA variant in complex with MHC class II reveals the ability of SEA to crosslink MHC molecules. Structure 10:1619–1626 http://dx.doi.org/10.1016/S0969-2126(02)00895-X. [PubMed]
59. Massell BF, Chute CG, Walker AM, Kurland GS. 1988. Penicillin and the marked decrease in morbidity and mortality from rheumatic fever in the United States. N Engl J Med 318:280–286 http://dx.doi.org/10.1056/NEJM198802043180504. [PubMed]
60. Cone LA, Woodard DR, Schlievert PM, Tomory GS. 1987. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 317:146–149 http://dx.doi.org/10.1056/NEJM198707163170305. [PubMed]
61. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, Kaplan E. 1989. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 321:1–7 http://dx.doi.org/10.1056/NEJM198907063210101. [PubMed]
62. Cleary PP, Kaplan EL, Handley JP, Wlazlo A, Kim MH, Hauser AR, Schlievert PM. 1992. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 339:518–521 http://dx.doi.org/10.1016/0140-6736(92)90339-5.
63. Musser JM, Kapur V, Szeto J, Pan X, Swanson DS, Martin DR. 1995. Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Infect Immun 63:994–1003. [PubMed]
64. Schlievert PM, Assimacopoulos AP, Cleary PP. 1996. Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. J Lab Clin Med 127:13–22 http://dx.doi.org/10.1016/S0022-2143(96)90161-4.
65. Sumby P, Porcella SF, Madrigal AG, Barbian KD, Virtaneva K, Ricklefs SM, Sturdevant DE, Graham MR, Vuopio-Varkila J, Hoe NP, Musser JM. 2005. Evolutionary origin and emergence of a highly successful clone of serotype M1 group A Streptococcus involved multiple horizontal gene transfer events. J Infect Dis 192:771–782 http://dx.doi.org/10.1086/432514. [PubMed]
66. Maamary PG, Ben Zakour NL, Cole JN, Hollands A, Aziz RK, Barnett TC, Cork AJ, Henningham A, Sanderson-Smith M, McArthur JD, Venturini C, Gillen CM, Kirk JK, Johnson DR, Taylor WL, Kaplan EL, Kotb M, Nizet V, Beatson SA, Walker MJ, Zakour B. 2012. Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clone. FASEB J 26:4675–4684 http://dx.doi.org/10.1096/fj.12-212142. [PubMed]
67. Liu Y, Chan TC, Yap LW, Luo Y, Xu W, Qin S, Zhao N, Yu Z, Geng X, Liu SL. 2018. Resurgence of scarlet fever in China: a 13-year population-based surveillance study. Lancet Infect Dis 18:903–912 http://dx.doi.org/10.1016/S1473-3099(18)30231-7.
68. Lamagni T, Guy R, Chand M, Henderson KL, Chalker V, Lewis J, Saliba V, Elliot AJ, Smith GE, Rushton S, Sheridan EA, Ramsay M, Johnson AP. 2018. Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study. Lancet Infect Dis 18:180–187 http://dx.doi.org/10.1016/S1473-3099(17)30693-X. [PubMed]
69. Park DW, Kim SH, Park JW, Kim MJ, Cho SJ, Park HJ, Jung SH, Seo MH, Lee YS, Kim BH, Min H, Lee SY, Ha DR, Kim ES, Hong Y, Chung JK. 2017. Incidence and characteristics of scarlet fever, South Korea, 2008-2015. Emerg Infect Dis 23:658–661 http://dx.doi.org/10.3201/eid2304.160773. [PubMed]
70. Brockmann SO, Eichner L, Eichner M. 2018. Constantly high incidence of scarlet fever in Germany. Lancet Infect Dis 18:499–500 http://dx.doi.org/10.1016/S1473-3099(18)30210-X.
71. Davies MR, Holden MT, Coupland P, Chen JHK, Venturini C, Barnett TC, Zakour NL, Tse H, Dougan G, Yuen K-Y, Walker MJ. 2015. Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nat Genet 47:84–87 http://dx.doi.org/10.1038/ng.3147. [PubMed]
72. Ben Zakour NL, Davies MR, You Y, Chen JHK, Forde BM, Stanton-Cook M, Yang R, Cui Y, Barnett TC, Venturini C, Ong CL, Tse H, Dougan G, Zhang J, Yuen K-Y, Beatson SA, Walker MJ. 2015. Transfer of scarlet fever-associated elements into the group A Streptococcus M1T1 clone. Sci Rep 5:15877 http://dx.doi.org/10.1038/srep15877. [PubMed]
73. Turner CE, Pyzio M, Song B, Lamagni T, Meltzer M, Chow JY, Efstratiou A, Curtis S, Sriskandan S. 2016. Scarlet fever upsurge in England and molecular-genetic analysis in North-West London, 2014. Emerg Infect Dis 22:1075–1078 http://dx.doi.org/10.3201/eid2206.151726. [PubMed]
74. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK. 1991. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A 88:2668–2672 http://dx.doi.org/10.1073/pnas.88.7.2668. [PubMed]
75. Cockerill FR III, MacDonald KL, Thompson RL, Roberson F, Kohner PC, Besser-Wiek J, Manahan JM, Musser JM, Schlievert PM, Talbot J, Frankfort B, Steckelberg JM, Wilson WR, Osterholm MT. 1997. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 277:38–43 http://dx.doi.org/10.1001/jama.1997.03540250046030. [PubMed]
76. Demers B, Simor AE, Vellend H, Schlievert PM, Byrne S, Jamieson F, Walmsley S, Low DE. 1993. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 16:792–800, discussion 801–802 http://dx.doi.org/10.1093/clind/16.6.792. [PubMed]
77. Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. 1991. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 29:1562–1567. [PubMed]
78. Holm SE, Norrby A, Bergholm AM, Norgren M. 1992. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 166:31–37 http://dx.doi.org/10.1093/infdis/166.1.31. [PubMed]
79. Roggiani M, Stoehr JA, Olmsted SB, Matsuka YV, Pillai S, Ohlendorf DH, Schlievert PM. 2000. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun 68:5011–5017 http://dx.doi.org/10.1128/IAI.68.9.5011-5017.2000. [PubMed]
80. Bessen DE, Izzo MW, Fiorentino TR, Caringal RM, Hollingshead SK, Beall B. 1999. Genetic linkage of exotoxin alleles and emm gene markers for tissue tropism in group A streptococci. J Infect Dis 179:627–636 http://dx.doi.org/10.1086/314631. [PubMed]
81. Nelson K, Schlievert PM, Selander RK, Musser JM. 1991. Characterization and clonal distribution of four alleles of the speA gene encoding pyrogenic exotoxin A (scarlet fever toxin) in Streptococcus pyogenes. J Exp Med 174:1271–1274 http://dx.doi.org/10.1084/jem.174.5.1271. [PubMed]
82. McCormick JK, Pragman AA, Stolpa JC, Leung DYM, Schlievert PM. 2001. Functional characterization of streptococcal pyrogenic exotoxin J, a novel superantigen. Infect Immun 69:1381–1388 http://dx.doi.org/10.1128/IAI.69.3.1381-1388.2001. [PubMed]
83. Sriskandan S, Moyes D, Cohen J. 1996. Detection of circulating bacterial superantigen and lymphotoxin-alpha in patients with streptococcal toxic-shock syndrome. Lancet 348:1315–1316 http://dx.doi.org/10.1016/S0140-6736(05)65800-X.
84. Basma H, Norrby-Teglund A, Guedez Y, McGeer A, Low DE, El-Ahmedy O, Schwartz B, Kotb M. 1999. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun 67:1871–1877. [PubMed]
85. Eriksson BK, Andersson J, Holm SE, Norgren M. 1999. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 180:410–418 http://dx.doi.org/10.1086/314872. [PubMed]
86. Parsonnet J, Gillis ZA, Richter AG, Pier GB. 1987. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun 55:1070–1076. [PubMed]
87. Sriskandan S, Unnikrishnan M, Krausz T, Cohen J. 1999. Molecular analysis of the role of streptococcal pyrogenic exotoxin A (SPEA) in invasive soft-tissue infection resulting from Streptococcus pyogenes. Mol Microbiol 33:778–790 http://dx.doi.org/10.1046/j.1365-2958.1999.01525.x. [PubMed]
88. Unnikrishnan M, Cohen J, Sriskandan S. 2001. Complementation of a speA negative Streptococcus pyogenes with speA: effects on virulence and production of streptococcal pyrogenic exotoxin A. Microb Pathog 31:109–114 http://dx.doi.org/10.1006/mpat.2001.0453. [PubMed]
89. Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, Khurshid A, Green K, Peeples J, Wade J, Thomson G, Schwartz B, Low DE. 2002. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 8:1398–1404 http://dx.doi.org/10.1038/nm1202-800. [PubMed]
90. Norrby-Teglund A, Nepom GT, Kotb M. 2002. Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alleles. Eur J Immunol 32:2570–2577 http://dx.doi.org/10.1002/1521-4141(200209)32:9<2570::AID-IMMU2570>3.0.CO;2-E.
91. Llewelyn M, Sriskandan S, Peakman M, Ambrozak DR, Douek DC, Kwok WW, Cohen J, Altmann DM. 2004. HLA class II polymorphisms determine responses to bacterial superantigens. J Immunol 172:1719–1726 http://dx.doi.org/10.4049/jimmunol.172.3.1719. [PubMed]
92. Kasper KJ, Zeppa JJ, Wakabayashi AT, Xu SX, Mazzuca DM, Welch I, Baroja ML, Kotb M, Cairns E, Cleary PP, Haeryfar SMM, McCormick JK. 2014. Bacterial superantigens promote acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC class II-dependent manner. PLoS Pathog 10:e1004155 http://dx.doi.org/10.1371/journal.ppat.1004155. [PubMed]
93. Zeppa JJ, Wakabayashi AT, Kasper KJ, Xu SX, Haeryfar SMM, McCormick JK. 2016. Nasopharyngeal infection of mice with Streptococcus pyogenes and in vivo detection of superantigen activity. Methods Mol Biol 1396:95–107 http://dx.doi.org/10.1007/978-1-4939-3344-0_8. [PubMed]
94. Zeppa JJ, Kasper KJ, Mohorovic I, Mazzuca DM, Haeryfar SMM, McCormick JK. 2017. Nasopharyngeal infection by Streptococcus pyogenes requires superantigen-responsive Vβ-specific T cells. Proc Natl Acad Sci U S A 114:10226–10231 http://dx.doi.org/10.1073/pnas.1700858114. [PubMed]
95. Chaussee MS, Phillips ER, Ferretti JJ. 1997. Temporal production of streptococcal erythrogenic toxin B (streptococcal cysteine proteinase) in response to nutrient depletion. Infect Immun 65:1956–1959. [PubMed]
96. Yu CE, Ferretti JJ. 1991. Frequency of the erythrogenic toxin B and C genes ( speB and speC) among clinical isolates of group A streptococci. Infect Immun 59:211–215. [PubMed]
97. Bustin M, Lin MC, Stein WH, Moore S. 1970. Activity of the reduced zymogen of streptococcal proteinase. J Biol Chem 245:846–849. [PubMed]
98. Doran JD, Nomizu M, Takebe S, Ménard R, Griffith D, Ziomek E. 1999. Autocatalytic processing of the streptococcal cysteine protease zymogen: processing mechanism and characterization of the autoproteolytic cleavage sites. Eur J Biochem 263:145–151 http://dx.doi.org/10.1046/j.1432-1327.1999.00473.x. [PubMed]
99. Kagawa TF, O’Toole PW, Cooney JC. 2005. SpeB-Spi: a novel protease-inhibitor pair from Streptococcus pyogenes. Mol Microbiol 57:650–666 http://dx.doi.org/10.1111/j.1365-2958.2005.04708.x. [PubMed]
100. Ly AT, Noto JP, Walwyn OL, Tanz RR, Shulman ST, Kabat W, Bessen DE. 2017. Differences in SpeB protease activity among group A streptococci associated with superficial, invasive, and autoimmune disease. PLoS One 12:e0177784 http://dx.doi.org/10.1371/journal.pone.0177784. [PubMed]
101. Collin M, Olsén A. 2003. Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes. Infect Immun 71:2983–2992 http://dx.doi.org/10.1128/IAI.71.6.2983-2992.2003. [PubMed]
102. Kapur V, Majesky MW, Li LL, Black RA, Musser JM. 1993. Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci U S A 90:7676–7680 http://dx.doi.org/10.1073/pnas.90.16.7676. [PubMed]
103. Matsuka YV, Pillai S, Gubba S, Musser JM, Olmsted SB. 1999. Fibrinogen cleavage by the Streptococcus pyogenes extracellular cysteine protease and generation of antibodies that inhibit enzyme proteolytic activity. Infect Immun 67:4326–4333. [PubMed]
104. Kapur V, Topouzis S, Majesky MW, Li L-L, Hamrick MR, Hamill RJ, Patti JM, Musser JM. 1993. A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb Pathog 15:327–346 http://dx.doi.org/10.1006/mpat.1993.1083. [PubMed]
105. Herwald H, Collin M, Müller-Esterl W, Björck L. 1996. Streptococcal cysteine proteinase releases kinins: a virulence mechanism. J Exp Med 184:665–673 http://dx.doi.org/10.1084/jem.184.2.665. [PubMed]
106. Burns EH Jr, Marciel AM, Musser JM. 1996. Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease. Infect Immun 64:4744–4750. [PubMed]
107. Persson H, Vindebro R, von Pawel-Rammingen U. 2013. The streptococcal cysteine protease SpeB is not a natural immunoglobulin-cleaving enzyme. Infect Immun 81:2236–2241 http://dx.doi.org/10.1128/IAI.00168-13. [PubMed]
108. Kuo CF, Lin YS, Chuang WJ, Wu JJ, Tsao N. 2008. Degradation of complement 3 by streptococcal pyrogenic exotoxin B inhibits complement activation and neutrophil opsonophagocytosis. Infect Immun 76:1163–1169 http://dx.doi.org/10.1128/IAI.01116-07. [PubMed]
109. Honda-Ogawa M, Ogawa T, Terao Y, Sumitomo T, Nakata M, Ikebe K, Maeda Y, Kawabata S. 2013. Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors. J Biol Chem 288:15854–15864 http://dx.doi.org/10.1074/jbc.M113.469106. [PubMed]
110. Egesten A, Olin AI, Linge HM, Yadav M, Mörgelin M, Karlsson A, Collin M. 2009. SpeB of Streptococcus pyogenes differentially modulates antibacterial and receptor activating properties of human chemokines. PLoS One 4:e4769 http://dx.doi.org/10.1371/journal.pone.0004769. [PubMed]
111. Sumitomo T, Nakata M, Higashino M, Terao Y, Kawabata S. 2013. Group A streptococcal cysteine protease cleaves epithelial junctions and contributes to bacterial translocation. J Biol Chem 288:13317–13324 http://dx.doi.org/10.1074/jbc.M113.459875. [PubMed]
112. Sumitomo T, Mori Y, Nakamura Y, Honda-Ogawa M, Nakagawa S, Yamaguchi M, Matsue H, Terao Y, Nakata M, Kawabata S. 2018. Streptococcal cysteine protease-mediated cleavage of desmogleins is involved in the pathogenesis of cutaneous infection. Front Cell Infect Microbiol 8:10 http://dx.doi.org/10.3389/fcimb.2018.00010. [PubMed]
113. Berge A, Björck L. 1995. Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins. J Biol Chem 270:9862–9867 http://dx.doi.org/10.1074/jbc.270.17.9862. [PubMed]
114. Kansal RG, Nizet V, Jeng A, Chuang WJ, Kotb M. 2003. Selective modulation of superantigen-induced responses by streptococcal cysteine protease. J Infect Dis 187:398–407 http://dx.doi.org/10.1086/368022. [PubMed]
115. Nooh MM, Aziz RK, Kotb M, Eroshkin A, Chuang WJ, Proft T, Kansal R. 2006. Streptococcal mitogenic exotoxin, SmeZ, is the most susceptible M1T1 streptococcal superantigen to degradation by the streptococcal cysteine protease, SpeB. J Biol Chem 281:35281–35288 http://dx.doi.org/10.1074/jbc.M605544200.
116. Nyberg P, Rasmussen M, Von Pawel-Rammingen U, Björck L. 2004. SpeB modulates fibronectin-dependent internalization of Streptococcus pyogenes by efficient proteolysis of cell-wall-anchored protein F1. Microbiology 150:1559–1569 http://dx.doi.org/10.1099/mic.0.27076-0. [PubMed]
117. Lukomski S, Burns EH Jr, Wyde PR, Podbielski A, Rurangirwa J, Moore-Poveda DK, Musser JM. 1998. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun 66:771–776. [PubMed]
118. Kansal RG, McGeer A, Low DE, Norrby-Teglund A, Kotb M. 2000. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect Immun 68:6362–6369 http://dx.doi.org/10.1128/IAI.68.11.6362-6369.2000. [PubMed]
119. Aziz RK, Pabst MJ, Jeng A, Kansal R, Low DE, Nizet V, Kotb M. 2004. Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Mol Microbiol 51:123–134 http://dx.doi.org/10.1046/j.1365-2958.2003.03797.x. [PubMed]
120. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. 2006. Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog 2:e5 http://dx.doi.org/10.1371/journal.ppat.0020005. [PubMed]
121. Rasmussen M, Björck L. 2002. Proteolysis and its regulation at the surface of Streptococcus pyogenes. Mol Microbiol 43:537–544 http://dx.doi.org/10.1046/j.1365-2958.2002.02766.x. [PubMed]
122. Olsen RJ, Sitkiewicz I, Ayeras AA, Gonulal VE, Cantu C, Beres SB, Green NM, Lei B, Humbird T, Greaver J, Chang E, Ragasa WP, Montgomery CA, Cartwright J Jr, McGeer A, Low DE, Whitney AR, Cagle PT, Blasdel TL, DeLeo FR, Musser JM. 2010. Decreased necrotizing fasciitis capacity caused by a single nucleotide mutation that alters a multiple gene virulence axis. Proc Natl Acad Sci U S A 107:888–893 http://dx.doi.org/10.1073/pnas.0911811107. [PubMed]
123. Ashbaugh CD, Wessels MR. 2001. Absence of a cysteine protease effect on bacterial virulence in two murine models of human invasive group A streptococcal infection. Infect Immun 69:6683–6688 http://dx.doi.org/10.1128/IAI.69.11.6683-6686.2001. [PubMed]
124. Remmington A, Turner CE. 2018. The DNases of pathogenic Lancefield streptococci. Microbiology 164:242–250 http://dx.doi.org/10.1099/mic.0.000612. [PubMed]
125. Matsumoto M, Sakae K, Hashikawa S, Torii K, Hasegawa T, Horii T, Endo M, Okuno R, Murayama S, Hirasawa K, Suzuki R, Isobe J, Tanaka D, Katsukawa C, Tamaru A, Tomita M, Ogata K, Ikebe T, Watanabe H, Ohta M, Working Group for Group A Streptococci in Japan. 2005. Close correlation of streptococcal DNase B (sdaB) alleles with emm genotypes in Streptococcus pyogenes. Microbiol Immunol 49:925–929 http://dx.doi.org/10.1111/j.1348-0421.2005.tb03684.x. [PubMed]
126. Hasegawa T, Minami M, Okamoto A, Tatsuno I, Isaka M, Ohta M. 2010. Characterization of a virulence-associated and cell-wall-located DNase of Streptococcus pyogenes. Microbiology 156:184–190 http://dx.doi.org/10.1099/mic.0.031955-0. [PubMed]
127. Brinkmann V. 2004. Neutrophil extracellular traps kill bacteria. Science 303:1532–1535. [PubMed]
128. Chang A, Khemlani A, Kang H, Proft T. 2011. Functional analysis of Streptococcus pyogenes nuclease A (SpnA), a novel group A streptococcal virulence factor. Mol Microbiol 79:1629–1642 http://dx.doi.org/10.1111/j.1365-2958.2011.07550.x. [PubMed]
129. Sumby P, Barbian KD, Gardner DJ, Whitney AR, Welty DM, Long RD, Bailey JR, Parnell MJ, Hoe NP, Adams GG, Deleo FR, Musser JM. 2005. Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc Natl Acad Sci U S A 102:1679–1684 http://dx.doi.org/10.1073/pnas.0406641102. [PubMed]
130. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M, Feramisco J, Nizet V. 2006. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr Biol 16:396–400 http://dx.doi.org/10.1016/j.cub.2005.12.039. [PubMed]
131. Uchiyama S, Andreoni F, Schuepbach RA, Nizet V, Zinkernagel AS. 2012. DNase Sda1 allows invasive M1T1 group A Streptococcus to prevent TLR9-dependent recognition. PLoS Pathog 8:e1002736 http://dx.doi.org/10.1371/journal.ppat.1002736. [PubMed]
132. Akesson P, Sjöholm AG, Björck L. 1996. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Biol Chem 271:1081–1088 http://dx.doi.org/10.1074/jbc.271.2.1081. [PubMed]
133. Hoe NP, Kordari P, Cole R, Liu M, Palzkill T, Huang W, McLellan D, Adams GJ, Hu M, Vuopio-Varkila J, Cate TR, Pichichero ME, Edwards KM, Eskola J, Low DE, Musser JM. 2000. Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics. J Infect Dis 182:1425–1436 http://dx.doi.org/10.1086/315882. [PubMed]
134. Hoe NP, Nakashima K, Lukomski S, Grigsby D, Liu M, Kordari P, Dou SJ, Pan X, Vuopio-Varkila J, Salmelinna S, McGeer A, Low DE, Schwartz B, Schuchat A, Naidich S, De Lorenzo D, Fu YX, Musser JM. 1999. Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves. Nat Med 5:924–929 http://dx.doi.org/10.1038/11369. [PubMed]
135. Binks M, Sriprakash KS. 2004. Characterization of a complement-binding protein, DRS, from strains of Streptococcus pyogenes containing the emm12 and emm55 genes. Infect Immun 72:3981–3986 http://dx.doi.org/10.1128/IAI.72.7.3981-3986.2004. [PubMed]
136. Fernie-King BA, Seilly DJ, Willers C, Würzner R, Davies A, Lachmann PJ. 2001. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 103:390–398 http://dx.doi.org/10.1046/j.1365-2567.2001.01249.x. [PubMed]
137. Pence MA, Rooijakkers SHM, Cogen AL, Cole JN, Hollands A, Gallo RL, Nizet V. 2010. Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus. J Innate Immun 2:587–595 http://dx.doi.org/10.1159/000317672. [PubMed]
138. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. 2002. Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun 70:4908–4916 http://dx.doi.org/10.1128/IAI.70.9.4908-4916.2002. [PubMed]
139. Fernie-King BA, Seilly DJ, Lachmann PJ. 2004. The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins. Immunology 111:444–452 http://dx.doi.org/10.1111/j.0019-2805.2004.01837.x. [PubMed]
140. Frick I-M, Akesson P, Rasmussen M, Schmidtchen A, Björck L. 2003. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 278:16561–16566 http://dx.doi.org/10.1074/jbc.M301995200. [PubMed]
141. Akesson P, Herwald H, Rasmussen M, Håkansson K, Abrahamson M, Hasan AAK, Schmaier AH, Müller-Esterl W, Björck L. 2010. Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. Microbiology 156:3660–3668 http://dx.doi.org/10.1099/mic.0.039578-0. [PubMed]
142. Westman J, Chakrakodi B, Snäll J, Mörgelin M, Bruun Madsen M, Hyldegaard O, Neumann A, Frick I-M, Norrby-Teglund A, Björck L, Herwald H. 2018. Protein SIC secreted from Streptococcus pyogenes forms complexes with extracellular histones that boost cytokine production. Front Immunol 9:236 http://dx.doi.org/10.3389/fimmu.2018.00236.
143. Lukomski S, Hoe NP, Abdi I, Rurangirwa J, Kordari P, Liu M, Dou SJ, Adams GG, Musser JM. 2000. Nonpolar inactivation of the hypervariable streptococcal inhibitor of complement gene ( sic) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal colonization. Infect Immun 68:535–542 http://dx.doi.org/10.1128/IAI.68.2.535-542.2000.
144. von Pawel-Rammingen U, Johansson BP, Björck L. 2002. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 21:1607–1615 http://dx.doi.org/10.1093/emboj/21.7.1607. [PubMed]
145. Lei B, DeLeo FR, Hoe NP, Graham MR, Mackie SM, Cole RL, Liu M, Hill HR, Low DE, Federle MJ, Scott JR, Musser JM. 2001. Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nat Med 7:1298–1305 http://dx.doi.org/10.1038/nm1201-1298. [PubMed]
146. Okumura CYM, Anderson EL, Döhrmann S, Tran DN, Olson J, von Pawel-Rammingen U, Nizet V. 2013. IgG protease Mac/IdeS is not essential for phagocyte resistance or mouse virulence of M1T1 group A Streptococcus. MBio 4:e00499-13 http://dx.doi.org/10.1128/mBio.00499-13. [PubMed]
147. Collin M, Olsén A. 2001. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J 20:3046–3055 http://dx.doi.org/10.1093/emboj/20.12.3046. [PubMed]
148. Collin M, Svensson MD, Sjöholm AG, Jensenius JC, Sjöbring U, Olsén A. 2002. EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis. Infect Immun 70:6646–6651 http://dx.doi.org/10.1128/IAI.70.12.6646-6651.2002. [PubMed]
149. Sjögren J, Okumura CY, Collin M, Nizet V, Hollands A. 2011. Study of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence. BMC Microbiol 11:120 http://dx.doi.org/10.1186/1471-2180-11-120. [PubMed]
150. Wang X, Lin X, Loy JA, Tang J, Zhang XC. 1998. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 281:1662–1665 http://dx.doi.org/10.1126/science.281.5383.1662. [PubMed]
151. Parry MA, Zhang XC, Bode I. 2000. Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem Sci 25:53–59 http://dx.doi.org/10.1016/S0968-0004(99)01521-2.
152. Walker MJ, McArthur JD, McKay F, Ranson M. 2005. Is plasminogen deployed as a Streptococcus pyogenes virulence factor? Trends Microbiol 13:308–313 http://dx.doi.org/10.1016/j.tim.2005.05.006. [PubMed]
153. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. 1995. The cell biology of the plasminogen system. FASEB J 9:939–945 http://dx.doi.org/10.1096/fasebj.9.10.7615163. [PubMed]
154. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, Rozek LS, Wang X, Sjöbring U, Ginsburg D. 2004. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305:1283–1286 http://dx.doi.org/10.1126/science.1101245. [PubMed]
155. Sanderson-Smith ML, De Oliveira DMP, Ranson M, McArthur JD. 2012. Bacterial plasminogen receptors: mediators of a multifaceted relationship. J Biomed Biotechnol 2012:272148 http://dx.doi.org/10.1155/2012/272148. [PubMed]
156. Ly D, Taylor JM, Tsatsaronis JA, Monteleone MM, Skora AS, Donald CA, Maddocks T, Nizet V, West NP, Ranson M, Walker MJ, McArthur JD, Sanderson-Smith ML. 2014. Plasmin(ogen) acquisition by group A Streptococcus protects against C3b-mediated neutrophil killing. J Innate Immun 6:240–250 http://dx.doi.org/10.1159/000353754. [PubMed]
157. Nitzsche R, Köhler J, Kreikemeyer B, Oehmcke-Hecht S. 2016. Streptococcus pyogenes escapes killing from extracellular histones through plasminogen binding and activation by streptokinase. J Innate Immun 8:589–600 http://dx.doi.org/10.1159/000448039. [PubMed]
158. Nitzsche R, Rosenheinrich M, Kreikemeyer B, Oehmcke-Hecht S. 2015. Streptococcus pyogenes triggers activation of the human contact system by streptokinase. Infect Immun 83:3035–3042 http://dx.doi.org/10.1128/IAI.00180-15. [PubMed]
159. Olsen RJ, Shelburne SA, Musser JM. 2009. Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol 11:1–12 http://dx.doi.org/10.1111/j.1462-5822.2008.01225.x. [PubMed]
160. Frick I-M, Björck L, Herwald H. 2007. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 98:497–502 http://dx.doi.org/10.1160/TH07-01-0051. [PubMed]
161. Banks DJ, Beres SB, Musser JM. 2002. The fundamental contribution of phages to GAS evolution, genome diversification and strain emergence. Trends Microbiol 10:515–521 http://dx.doi.org/10.1016/S0966-842X(02)02461-7.
162. Beres SB, Musser JM. 2007. Contribution of exogenous genetic elements to the group A Streptococcus metagenome. PLoS One 2:e800 http://dx.doi.org/10.1371/journal.pone.0000800. [PubMed]
163. Accardo P, Sánchez-Corral P, Criado O, García E, Rodríguez de Córdoba S. 1996. Binding of human complement component C4b-binding protein (C4BP) to Streptococcus pyogenes involves the C4b-binding site. J Immunol 157:4935–4939. [PubMed]
164. Gustafsson MCU, Lannergård J, Nilsson OR, Kristensen BM, Olsen JE, Harris CL, Ufret-Vincenty RL, Stålhammar-Carlemalm M, Lindahl G. 2013. Factor H binds to the hypervariable region of many Streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence. PLoS Pathog 9:e1003323 http://dx.doi.org/10.1371/journal.ppat.1003323.
165. Ermert D, Shaughnessy J, Joeris T, Kaplan J, Pang CJ, Kurt-Jones EA, Rice PA, Ram S, Blom AM. 2015. Virulence of group A streptococci is enhanced by human complement inhibitors. PLoS Pathog 11:e1005043 http://dx.doi.org/10.1371/journal.ppat.1005043.
166. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680 http://dx.doi.org/10.1093/nar/22.22.4673.
167. Kumar S, Stecher G, Tamura K. 2016. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for bigger datasets. Mol Biol Evol 33:1870–1874 http://dx.doi.org/10.1093/molbev/msw054.
168. Brouillard J-NP, Günther S, Varma AK, Gryski I, Herfst CA, Rahman AKMN, Leung DYM, Schlievert PM, Madrenas J, Sundberg EJ, McCormick JK. 2007. Crystal structure of the streptococcal superantigen SpeI and functional role of a novel loop domain in T cell activation by group V superantigens. J Mol Biol 367:925–934 http://dx.doi.org/10.1016/j.jmb.2007.01.024.
169. Li Y, Li H, Dimasi N, McCormick JK, Martin R, Schuck P, Schlievert PM, Mariuzza RA. 2001. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity 14:93–104 http://dx.doi.org/10.1016/S1074-7613(01)00092-9.
170. Kasper KJ, Xi W, Rahman AKMN-U, Nooh MM, Kotb M, Sundberg EJ, Madrenas J, McCormick JK. 2008. Molecular requirements for MHC class II alpha-chain engagement and allelic discrimination by the bacterial superantigen streptococcal pyrogenic exotoxin C. J Immunol 181:3384–3392 http://dx.doi.org/10.4049/jimmunol.181.5.3384.
171. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, Stauffacher C, Strominger JL, Wiley DC. 1994. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368:711–718 http://dx.doi.org/10.1038/368711a0.
Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.GPP3-0054-2018
2019-02-08
2019-02-23

Abstract:

(i.e., the group A ) is a human-restricted and versatile bacterial pathogen that produces an impressive arsenal of both surface-expressed and secreted virulence factors. Although surface-expressed virulence factors are clearly vital for colonization, establishing infection, and the development of disease, the secreted virulence factors are likely the major mediators of tissue damage and toxicity seen during active infection. The collective exotoxin arsenal of is rivaled by few bacterial pathogens and includes extracellular enzymes, membrane active proteins, and a variety of toxins that specifically target both the innate and adaptive arms of the immune system, including the superantigens; however, despite their role in disease, each of these virulence factors has likely evolved with humans in the context of asymptomatic colonization and transmission. In this article, we focus on the biology of the true secreted exotoxins of the group A , as well as their roles in the pathogenesis of human disease.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Phylogenetic relationships and structural conservation of the streptococcal superantigens. Unrooted neighbor-joining tree showing phylogenetic relationships of known streptococcal superantigens. The unrooted tree was based on the alignment of amino acid sequences using CLUSTAL W ( 166 ) and constructed using MEGA7 ( 167 ). The groups indicate a prior classification scheme for the superantigen family ( 32 ). Amino acid alignment of five representative streptococcal superantigens. The colors designate distinct domains in the superantigen structure, including the N-terminal α-helix (green), the central α-helix (red), the α3-β8 loop that is unique to the group V superantigens ( 168 ), and a C-terminal α-helix that is lacking in a subgroup of group IV. Residues involved in the coordination of a zinc atom important for binding to the MHC class II β-chain are colored magenta. Crystal structures of representative streptococcal superantigens are colored as in panel B.

Source: microbiolspec February 2019 vol. 7 no. 1 doi:10.1128/microbiolspec.GPP3-0054-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Models of T cell activation complexes for streptococcal superantigens. Ribbon diagrams demonstrating typical antigen-mediated T cell activation and modeled T cell activation complexes for SpeA and SpeC . The cocrystal structures of SpeA and SpeC in complex with their respective TCR β-chains ( 48 ) and of SpeC in complex with the MHC class II through the zinc-dependent high-affinity binding domain have been determined ( 169 ). SpeC also activates T cells in a mode similar to the staphylococcal enterotoxin A model ( 58 ) where SpeC engages MHC class II α-chain through a generic low-affinity binding domain ( 170 ) and engages the MHC class II β-chain through a zinc-dependent, high-affinity binding domain ( 169 ). The binding architecture for the generic low-affinity MHC class II binding to SpeA and SpeC is modeled using the staphylococcal enterotoxin B-MHC class II cocrystal structure ( 171 ). Note the presence of the zinc ion (magenta) coordinated in the high-affinity binding site for SpeC and that SpeA lacks this zinc site. The TCR α-chain (shown in gray) for both the SpeA and SpeC diagrams is modeled for clarity by superimposition of the α/β TCR shown on the left of the respective TCR β-chains for both superantigens. The figure was generated using Pymol.

Source: microbiolspec February 2019 vol. 7 no. 1 doi:10.1128/microbiolspec.GPP3-0054-2018
Permissions and Reprints Request Permissions
Download as Powerpoint

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error